Hoang le, MD
Pulmonary Disease · Fountain Valley, CANPI 1104886241
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $638,739 of the $814,200 with a category attached, or 78.4%. 17 manufacturers reported payments, led by AstraZeneca at 45.0% of the total. Reporting peaked in 2023 at $233,912 and has fallen 57.0% since, to $100,543 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,126 payments — averaging $723.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$366K
- GSK$258K
- Sunovion Pharmaceuticals Inc.$75K
- Mylan Specialty L.p.$43K
- Verona Pharma, Inc.$17K
- Regeneron Healthcare Solutions, Inc.$12K
- plus $43K from 11 others
What the payments were for
- Consulting fees$57,9407%
- Speaking & faculty fees$638,73978%
- Travel & lodging$88,95111%
- Food & beverage$28,4623%
- Education$1090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 469 | $366,339 |
| GSK | 309 | $257,617 |
| Sunovion Pharmaceuticals Inc. | 117 | $74,977 |
| Mylan Specialty L.p. | 99 | $43,227 |
| Verona Pharma, Inc. | 17 | $17,389 |
| Regeneron Healthcare Solutions, Inc. | 12 | $11,701 |
| Boehringer Ingelheim | 33 | $11,137 |
| Viatris Specialty LLC | 25 | $10,735 |
| Astrazeneca UK Limited | 8 | $9,926 |
| Portola Pharmaceuticals, LLC | 4 | $4,246 |
| Sanofi | 10 | $2,999 |
| Edwards Lifesciences | 2 | $1,600 |
| Johnson & Johnson(2 entities) | 15 | $1,425 |
| Verathon Inc. | 1 | $500 |
| Pulmonx Corporation | 1 | $150 |
| Harmony Biosciences LLC | 3 | $122 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $111 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$291,277
- AREXVY$148,103
- LONHALA MAGNAIR$68,147
- TRELEGY ELLIPTA$65,271
- Yupelri$53,217
- AIRSUPRA$49,543
- Ohtuvayre$17,315
- DUPIXENT$14,254
- BREZTRI AEROSPHERE$8,442
- LATUDA$5,002
- BEVYXXA$4,246
- Monarch Platform$956
- B Flex$500
- NUCALA$393
- OFEV$352
- SYMBICORT$300
- CHARTIS CATHETER$150
- ZEPHYR DELIVERY CATHETER$150
- ZEPHYR ENDOBRONCHIAL VALVE$150
- PULMONX CHARTIS TABLET CONSOLE$150
How this compares
$814,200 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,648 | $1,418,066 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 1,025 | $684,639 |
| OfevNintedanib Esylate | 51 | $672,559 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 427 | $236,565 |
| Breo ElliptaFluticasone/Vilanterol | 172 | $85,413 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $45,472 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,067 | $45,267 |
| Ventolin HfaAlbuterol Sulfate | 512 | $30,208 |
| Spiriva RespimatTiotropium Bromide | 21 | $18,282 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $15,212 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $14,579 |
| Spiriva HandihalerTiotropium Bromide | 22 | $12,816 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 31 | $7,767 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 11 | $5,706 |
| Roflumilast | 36 | $5,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $257,617 | $1,755,2562,275 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $11,137 | $736,313119 claims |
| AstraZenecaBreztri Aerosphere | $366,339 | $684,6391,025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Fountain Valley
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
- Victor TapsonLos Angeles$514K
- Rajan SaggarLos Angeles$480K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.